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3Abstract 
Mesenchymal stem cell (MSC) immunosuppressive functions make them attractive candidates 
for anti-inflammatory therapy in allergic asthma. However the mechanisms by which they 
ensure therapeutic effects remain to be elucidated. In an acute mouse model of house dust 
mite (Der f)-induced asthma, one i.v. MSC injection was sufficient to normalize and stabilize 
lung function in Der f-sensitized mice as compared to control mice. MSC injection decreased 
in vivo airway responsiveness and decreased ex vivo carbachol-induced bronchial contraction, 
maintaining bronchial expression of the inhibitory type 2 muscarinic receptor. To evaluate in 
vivo MSC survival, MSCs were labelled with PKH26 fluorescent marker prior to i.v. 
injection, and 1 to 10 days later total lungs were digested to obtain single-cell suspensions. 
91.5 ± 2.3% and 86.6 ± 6.3% of the recovered PKH26
+
 lung cells expressed specific
macrophage markers in control and Der f mice respectively, suggesting that macrophages had 
phagocyted in vivo the injected MSCs. Interestingly, only PKH26
+
 macrophages expressed
M2 phenotype, while the innate PKH26
-
 macrophages expressed M1 phenotype. Finally, the
remaining 0.5% PKH26
+
 MSCs expressed 10 to 100 fold more COX-2 than before injection,
suggesting in vivo MSC phenotype modification. Together, the results of this study indicate 
that MSCs attenuate asthma by being phagocyted by lung macrophages, which in turn acquire 
a M2 suppressive phenotype. 
Page 3 of 37 Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4Introduction 
Growing bodies of evidences support the potent role of mesenchymal stem cells (MSCs) in 
the suppression of exacerbated inflammation [1, 2]. Based on these observations, MSCs are 
now used in pre-clinical animal models and human clinical trials as an alternative therapeutic 
strategy to suppress deleterious immune responses in the context of acute graft-versus-host 
disease [3], autoimmunity [4, 5] and interestingly in a variety of lung disorders [6, 7]. 
Altogether, more than 150 clinical trials have been registered on the NIH clinical trial 
registry, including the injection of MSCs [8]. 
Allergic asthma is a chronic inflammatory disease characterized by airway hyper-
responsiveness and deregulated inflammation in response to allergens. This pathology is 
essentially controlled by CD4
+
 T helper 2 (TH2) lymphocytes, which cause cellular infiltration
in the lungs, overproduction of mucus and hyper-responsiveness. Some recent reports have 
highlighted the therapeutic efficacy of MSC injection, in both acute and chronic mouse 
models of asthma, by notably inducing the production of TGF-β [9], IL-10 [10], IFNγ [11, 
12], increasing Treg cell number [13], and modulating the TH1-TH2 immunological balance 
[11, 14]. However despite these observations, very little is known about the exact mechanisms 
mediated by MSCs in lung, as the largest part of injected cells does not integrate the lungs [9, 
15]. The therapeutic MSC effect has been attributed in part to paracrine effectors [16] 
including interaction with macrophages [15] via the PGE2 pathway [17, 18]. 
In this study, we took advantage of an acute model of house dust mite asthma to evaluate the 
mechanisms responsible for therapeutic efficacy of MSCs. Our data demonstrate that a single 
injection of MSCs improved lung function, inhibited contractile response of bronchi, 
decreased lung inflammation, and MSCs were in vivo phagocyted by lung macrophages which 
in turn acquired a M2 suppressor phenotype. 
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5Materials and Methods 
Protocol - Allergic asthma was induced in 6- to 8-week-old BALB/c mice (Charles River 
Laboratories) using total Der f extracts (Dermatophagoïdes farinae) provided by Stallergenes 
as previously described [19]. The Regional Ethical Committee for Animal Experiments of the 
Pays de la Loire (CEEA.2010.50) approved all animal protocols. In brief, mice were 
sensitized at day 0, 7, 14 and 21 by percutaneous application of 500µg of Der f extracts in 
20µL of dimethylsulfoxide (DMSO, Sigma-Aldrich) on the ears, and challenged intranasally 
with 250µg of Der f extracts in 40µL PBS at day 27 and 34 (Fig. 1). Control mice received 
only percutaneous application of 20µL DMSO and were challenged intranasally with PBS. 
During the first Der f challenge at day 27, mice also received 5.10
5
 MSCs in 200µL of PBS
via tail vein injection, or 200µL PBS only. Lung function was analyzed by invasive method 
(Flexivent
®
) to evaluate airway resistance, in response to increased doses of methacholine (0,
5, 10, 15, 20mg/mL), according to the manufacturer instructions. Data were normalized to the 
results at 0 mg/mL dose. 
Bone marrow MSC culture - Total bone marrow was obtained from several BALB/c mice 
by flushing femurs and tibias with culture medium (alpha MEM with nucleosides, 10% FCS, 
2mM L-Glutamin, 100U/mL penicillin, 100µg/mL streptomycin, 2ng/mL human FGF2 
(AbCys)). Cells were cultured until confluence, detached by 0.5% trypsin-EDTA and passed 
for amplification. From passage 8, MSCs were characterized by flow cytometry (BD LSRII, 
BD Biosciences, BD FACSDiva™ software) for specific markers: Sca-1-PE (D7), CD11b-PE 
(M1/70, eBiosciences), CD44-PE (IM7), CD29-FITC (Ha2/5), CD45-PE (30-F11) (BD 
Biosciences), and for adipogenic and osteogenic differentiation capacity (see supplementary 
Fig. 1). 
Page 5 of 37 Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6Ex vivo airway smooth muscle contraction - 2 mm-long rings of primary bronchi were cut 
and mounted on a multichannel isometric myograph (Danish Myo Technology). The bronchi 
were maintained in an organ bath containing Krebs-Henseleit buffer at 37°C continuously 
aerated (95% O2 and 5% CO2). A pre-tension of 0,5mN was applied and maintained all along 
the protocol. After an equilibration period, cumulative dose-response curves in response to 
KCl were obtained. In a second time, cumulative dose-response curves were obtained in 
response to carbachol, an analogue of methacholine (Sigma Aldrich). 
Lung histology –Mice were euthanized for histology analysis at day 28 and 37. Lungs were 
inflated via the trachea with OCT diluted ½ in PBS, cryopreserved and sliced into continuous 
5µm thick cryosections. Immunolabelling was performed to detect leucocytes with anti-CD45 
antibody (Becton Dickinson) and cell nuclei with DAPI (Sigma Aldrich). After fluorescence 
microscopy analysis, the same sections were secondary stained with Hematoxyline-Eosin for 
light microscopy analysis. 
Bronchoalveolar lavage and lung digestion - Bronchoalveolar lavage fluid (BAL) was 
obtained by instilling intra-tracheally 1mL PBS until lungs were inflated uniformly, followed 
by slow aspiration. BAL was centrifuged, and cells were counted and labelled for flow 
cytometry. After blood cardiac puncture, lungs were removed, minced into small pieces, and 
digested in 10mL PBS with 3mg/mL collagenase type II (Gibco) and 3mg/mL DNase I 
(Roche) at 37°C for 1 hour under agitation, to obtain lung single-cell suspension. Lung 
suspensions were filtered through a 40µm nylon filter. Red blood cells were lysed (BD FACS 
Lysing Solution 1X (Becton Dickinson)) and the remaining cells were washed, counted and 
labelled for flow cytometry or lysed for RNA extraction. 
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Flow cytometry – BAL cells were stained for multiparameter flow cytometric analysis. 
Ly6G-PercP.Cy5.5 (1A8), CD8-APC-H7 (53-6.7) (BD Biosciences), CD3-APC (145.2C11), 
CD19-PeCy7 (1D3), F4/80-FITC (BM8) (eBioscience), CCR3-PE (83101, R&D systems), 
and DAPI were used to identify BAL-infiltrating cells, as previously described [20]. Briefly, 
stained cells were acquired on a BD LSR™ II (BD Biosciences) and analyzed using BD 
FACSDiva™ software (BD Biosciences). Dead cells were excluded using DAPI. After gating 
on live cells, polymorphonuclear neutrophils (Ly6G
hi
 F4/80
-
 cells), macrophages (large,
Ly6G
-
 F4/80
+
 cells), and eosinophils (F4/80
-
, Ly6G
-
, CCR3
+
 cells) were identified.
Lymphocytes were identified as follows: forward scatter (FSC)
lo
, side scatter (SSC)
lo
, F4/80
-
,
Ly6G
-
 and CCR3
-
 T (CD19
-
 CD3
+
) and B (CD19
+
 CD3
-
) cells were also identified.
To investigate the T helper responses, 8.10
5
 lung cells were transferred to a 96-well round-
bottom plate and then stimulated for 5h with a mixture containing phorbol 12-myristate 13-
acetate (PMA) (50ng/mL; Sigma-Aldrich) and ionomycin (500ng/mL; Sigma-Aldrich) 
together with either monensin (PMA + ionomycin + monensin; PIM) for TH17 analysis 
(2mg/mL; BD Biosciences) or brefeldin A for TH2 assessment (1mg/mL; BD Biosciences). 
For cytokine detection, the FcRs were blocked with mouse CD16/CD32 mAbs (eBioscience). 
Prior to surface-specific staining, the cells were stained with Fixable Viability Dye 450 (BD 
Biosciences) to exclude dead cells. The following antibodies were used for surface staining: 
CD3-PeCy7 (145-2C11) and CD8-APC-H7 (53-6.7) (BD Biosciences). The cells were then 
fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) and stained 
intracellularly with anti-IL-4 (11B11; eBioscience), -IL-5 (TRFK5; BD Pharmingen), -IL-10 
(JES5-16E3; BD Pharmingen), -IL-13 (eBio13A; eBioscience), -IL-17A (TC11-18H10; BD 
Biosciences) and –IFNγ (XMG1.2, BD Pharmingen) antibodies. 
For in vivo MSC detection, MSCs cells were labelled just before injection with PKH26 
according to manufacturer instructions (Red Fluorescent Cell Linker Kits for General Cell 
Membrane Labeling (Sigma Aldrich)). A total of 5.10
5
 PKH26
+
 MSCs were injected in mice.
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8Total lung cells were obtained 1 or 10 days later as indicated above and labelled with DAPI to 
select viable cells and CD11c-PeCy7 (N418) and F4/80-FITC (BM8) antibodies 
(eBioscience). Cells were sorted after gating for morphology (FSC-H vs FSC-A) and viability 
(negative for DAPI). On these gates, cells PKH26+ and PKH26- were identified and further 
selected for cell sorting by F4/80 and CD11c expression. MSCs were evaluated and purified 
as PKH26
+
CD11c
-
F4/80
-
 cells (see supplementary Fig. 2) and counted in Malassez cell.
RNA isolation, Reverse Transcription, Real-Time PCR - Total RNA was extracted from 
lung homogenates, primary bronchi, and sorted cells using RNeasy mini and micro kit 
(Qiagen) according to manufacturer’s instructions. Total RNA was reversely transcribed to 
cDNA using High Capacity cDNA Archive kit (Applied Biosystems). DNA templates were 
amplified by real-time quantitative PCR on the 7900 HT Fast Real-Time PCR System (ABI 
Prism, Applied Biosystems), using the Taqman® technology and commercial primers. Data 
were normalized to reference HPRT1 gene and were used for the 2
-dCT 
calculation. 2
-dCT 
corresponds to the ratio of each gene expression versus HPRT1 gene expression. 
Statistical analysis – Comparisons of experimental values between two groups were analyzed 
using the Mann Whitney test. All statistical analysis were performed in GraphPad Prism v5. A 
p-value < 0.05 was considered statistically significant. 
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9Results 
Mesenchymal stem cells inhibit airway hyper-responsiveness and bronchoconstriction 
To investigate the effect of MSC injection on allergic asthma, we used a well-established 
house dust mite (Der f)-induced asthma model [19] (Fig. 1). Mice were sensitized with 
percutaneous Der f extracts and then twice challenged with intranasal Der f extracts. A single 
i.v. injection of syngeneic MSCs was performed concomitantly to the first Der f challenge. 
One day after the second Der f challenge (day 35 post-sensitization) a decrease in airway 
hyper-responsiveness was observed in Der f mice injected with MSCs as compared to Der f 
mice injected with PBS (3.3 ± 1 in Der f + MSC mice vs 5.5 ± 2.1 cmHO ml
-1
s
-1
 in Der f +
PBS mice at 20mg/mL methacholine, p=0.012, Fig. 2A), while MSC injection had no 
deleterious effect on lung function in control mice (3.3 ± 1.05 cmHO ml
-1
s
-1
 in control + MSC
mice vs 3.03 ± 0.8 cmHO ml
-1
s
-1
 in control + PBS mice at 20mg/mL methacholine, p=0.3).
This beneficial effect on lung function was stable 3 days after the second challenge (day 37 
post-sensitization, 4.2 ± 1.9 in cmHO ml
-1
s
-1
 in Der f + MSC mice vs 8.2 ± 3.1 cmHO ml
-1
s
-1
in Der f + PBS mice at 20mg/mL methacholine, p=0.03). 
As exaggerated bronchial contraction in response to bronchoconstrictor agents is a specific 
feature of asthma, we evaluated if MSC i.v. injection altered the contractile bronchial 
response. Contractile force was quantified ex vivo on primary bronchi from Der f and control 
mice injected with MSCs or PBS, in response to KCl and carbachol (Fig. 2B). Consistent with 
our in vivo data on lung function, MSC injection during the first Der f challenge reduced 
carbachol-induced contraction when compared to Der f mice injected with PBS (2.1 ± 0.4 vs 
0.97 ± 0.12, p=0.002). Interestingly no difference was observed in KCl-induced contraction, 
suggesting that MSCs inhibited bronchoconstriction by regulating the muscarinic pathway. 
Der f mice injected with PBS displayed a decreased expression of the M2 muscarinic receptor 
in their bronchi, as compared to control mice injected with PBS or MSCs (Fig. 2C). In 
Page 9 of 37
ScholarOne Support: (434) 964-4100
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10
contrast Der f mice injected with MSCs displayed M2 muscarinic receptor expression similar 
to that of control mice injected with PBS or MSCs. MSCs had no effect on M3 muscarinic 
receptor expression. Collectively these data suggest that MSCs mediated their protective role 
in asthma in part by modulating the airway contractile response. 
Mesenchymal stem cells are located in lungs after i.v. injection 
The presence of MSCs in lungs after i.v. injection was investigated using immuno-histology 
analysis. MSCs were labelled prior injection with PKH26, a fluorescent red marker which
stably incorporates into cell membrane lipids. Successive immunofluorescence and 
histological analyses showed PKH26
+
 cell presence in alveolar and capillary walls, both in
control and Der f mice (Fig. 3). PKH26
+
 cells were also located in inflammatory infiltrates in
Der f mice (Fig 3, E and F). In both groups PKH26
+
 cells were still detected 10 days after
MSC injection (Fig 3, C-D and G-H). 
Quantification of mesenchymal stem cells in lungs after i.v injection 
One day after injection of PKH26
+
 labelled MSCs in control and Der f mice, lungs were
removed and digested, and lung cell suspensions were evaluated for the presence of PKH26
+
cells using flow cytometry (Fig. 4A, upper panel). A total of 4 ± 0.5 % and 2.8 ± 0.5 % lung 
cells were identified as PKH26
+
 in control and Der f mice, respectively (n=6 in each group).
Surprisingly, while 5.10
5
 PKH26
+
 MSCs had been injected, the absolute number of PKH26
+
cells detected in the lungs was 65 ± 35.10
3
 and 58 ± 26.10
3
 cells in control and Der f mice,
respectively, suggesting that a high proportion of injected MSCs were still present in the lungs 
(13 ± 7 and 11,6 ± 5% in control and Der f mice, respectively). To evaluate if these cells were 
in fact macrophages, PKH26
+
 cells were co-labelled in lung cell suspensions with antibodies
specific for macrophages (CD11c/F4/80). Importantly, two cell populations were easily 
distinguished into PKH26
+
 cell gate (Fig. 4A, lower panel), including a large majority of
Page 10 of 37Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11
PKH26
+
 cells positive for CD11c/F4/80 macrophage markers (91.5 ± 2.3% and 86.6 ± 6.3%
in control (n=6) and Der f (n=6) mice, respectively), and a minority of PKH26
+
 cells negative
for CD11c/F4/80 macrophage markers (4.27 ± 0.7% (n=6) and 5.74 ± 1.47% in control (n=6) 
and Der f mice (n=8), respectively). The absolute number of PKH26
+
CD11c
+
F4/80
+
 cells was
23 ± 15.10
3
 cells and 27 ± 7.10
3
 cells in control and Der f mice, accounting for 4.8 ± 2.9%
and 5.5 ± 1.4% of 5.10
5
 PKH26
+
 injected MSCs (Fig. 4C). The absolute number of
PKH26
+
CD11c
-
F4/80
-
 cells was 763 ± 1046 and 2506 ± 2446 in control and Der f mice,
represented 0.15 ± 0.2% and 0.5 ± 0.5% of 5.10
5
 PKH26
+
 injected MSCs (Fig. 4D). Absolute
cell numbers of both cell populations were not significantly different between both groups, 
suggesting that airway inflammation in sensitized mice did not increase cell engraftment. 
Both populations of PKH26
+
 cells were then sorted using CD11c and F4/80 markers, and
placed separately into cell culture plates in MSC culture medium. After 31 days of culture 
(Fig. 4B), PKH26
+
CD11c
-
F4/80
-
cells proliferated and expressed MSC phenotype (Sca-1
+
,
CD29
+
, CD44
+
, CD45
-
, CD11b
-
; supplementary Fig. 3), confirming that these cells were
injected PKH26
+
 MSCs. In marked contrast, PKH26
+
CD11c
+
F4/80
+
 cells did not proliferate
in culture (Fig. 4B) and still expressed macrophage specific markers (CD11c
+
/F4/80
+
)
confirming that these cells were macrophages (supplementary Fig. 3). Interestingly, 
PKH26
+
CD11c
-
F4/80
-
 cells were also observed 10 days after i.v. injection (0.06% and 0.1 ±
0.09% of 5.10
5
 PKH26
+
 injected MSCs in control (n=3) and Der f (n=2) mice respectively),
suggesting a mid-term survival of a very small number of MSCs in the lungs of mice (Fig. 
4D). Together these data suggest that the vast majority of PKH26
+
 injected MSCs had been
phagocyted by lung macrophages during the 24hr following i.v. injection. 
Injection of mesenchymal stem cells decrease airway inflammation 
Airway inflammation is another important feature of allergic asthma. The first challenge with 
Der f extracts in Der f mice induced the infiltration of both eosinophils and neutrophils in 
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BAL, associated with the expansion of lung lymphocytes (Fig. 5A). MSCs did not alter 
immunologic profile in control mice, suggesting no deleterious effect and no inflammation 
response due to MSC injection itself (Fig. 5A). Interestingly, 24 hours after the first Der f 
challenge (day 28), MSC injection inhibited airway inflammation with decreased absolute 
numbers of BAL neutrophils, eosinophils and lymphocytes. In parallel a decrease was 
observed in cytokine (IL-4, IL-5, IL-13 and IL-17) expression by lung CD4
+
 T cells (Fig. 5B)
while no significant effect was observed to IFNγ and IL-10 expression. These data 
demonstrate that MSCs early constrained airway inflammation, however this suppressive 
effect declined after a second challenge (data not shown) despite the persistence of decreased 
hyper-responsiveness (Fig. 2A). 
MSC injection induces lung macrophage polarization into suppressive phenotype 
To evaluate whether phagocytosis of MSCs by lung macrophages could alter their function 
and explain MSC suppressive effects, total lung cells were obtained from control and Der f 
mice injected with PKH26-labelled MSCs as described above. Lung macrophages were then 
cell-sorted according to their specific co-expression of CD11c and F4/80, and divided into 2 
sub-populations according to their differential PKH26 labelling. Both macrophage 
subpopulations were then evaluated for their gene expression in pro and anti-inflammatory 
cytokines. Interestingly, the functional profile of PKH26
+
 and PKH26
- 
macrophages was
different (Fig. 6A). PKH26
+
 macrophages expressed higher mRNA levels of TGFβ1 and IL-
10, two immunosuppressive cytokines that are typically increased in M2 macrophages [21]. In 
contrast, PKH26
-
 macrophages expressed M1 macrophage phenotype with higher levels of
IL-6. No difference in TNFα mRNA expression was observed. Importantly, no difference in 
cytokine expression in lung macrophages was observed between control and Der f mice both 
injected with MSCs, suggesting that the induction of M2 macrophage phenotype was due to 
MSC injection and not to Der f sensitization. We then evaluated if MSCs expressed in vivo 
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13
COX-2, a cyclo-oxygenase which catalyzes the rate-limiting step of prostaglandin formation, 
including PGE-2, a central molecule necessary for M2 macrophage activation [22]. To answer 
this question, COX-2 gene expression was quantified in PKH26
+
CD11c
-
F4/80
-
 cells, as these
cells were demonstrated above as being MSCs (Fig. 4B). Sorted PKH26
+
CD11c
-
F4/80
-
 cells
expressed significantly higher mRNA levels of COX-2 than MSCs before their injection (Fig. 
6B). The over-expression of COX-2 in MSCs was still observed 10 days after the first Der f 
challenge and MSC injection. No difference in COX-2 expression in PKH26
+
CD11c
-
F4/80
-
cells was observed between control and Der f mice injected with MSCs, suggesting that the 
increase in COX-2 expression was due to MSC injection and not to Der f sensitization. 
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Discussion 
Numerous studies on MSCs and asthma therapy showed that MSC i.v. injection attenuate 
airway inflammation and hyper-responsiveness [9, 11-13, 23, 24], but the lack of mechanistic 
explanation hampered this result, considering the very low quantity of cells that survive and 
graft in lung tissue after injection. In this study we showed that injected MSCs are in vivo 
phagocyted by lung macrophages that, in turn, reprogram into an immunosuppressive 
phenotype. 
Cell tracking after in vivo administration is one of the trickiest issues in cell therapy studies 
and results from lung studies remain controversial [25]. The use of GFP as a marker of stem 
cells obtained from bone marrow of GFP
+
 transgenic mice, can lead to errors in the presence
of autofluorescent structures [26]. Microscopy-based methods even when coupled with 
immunohistochemistry-based cell visualization and characterization suffer from low 
sensitivity and problems associated with reliable interpretation of images [27]. To circumvent 
this issue, we injected MSCs labelled with PKH26 red fluorescent marker, and sorted PKH26
+
cells by flow cytometry from digested total lungs, 1 to 10 days after MSC injection. Our 
initial results suggesting high lung MSC engraftment were similar to that observed using the 
same methodology in a model of rat lung injury [28]. Nevertheless, such high lung 
engraftment was in discrepancy with previous studies in numerous lung injury animal models 
of stem cell therapy [29, 30]. By using sophisticated microscopy methods such as 
fluorescence confocal deconvolution microscopy, the participation to the lungs of adult stem 
cells from bone marrow was evaluated between 0.1 and 1 % [31-34]. On the other hand, a 
critical role of macrophages has been suggested as immune effector in MSC therapy models. 
Macrophages play an important role in acute allergic lung inflammation [35, 36], and 
interaction with macrophages is necessary for an optimal therapeutic effect of MSCs [15]. 
Depletion of alveolar macrophages reverses the benefit of stem cell treatment [15] and 
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increases inflammation [36]. We thus raised the hypothesis that injected MSCs had been 
phagocyted by macrophages. Using specific markers for macrophages we demonstrated that 
the sorted lung PKH26
+
 cells were indeed mostly macrophages, whereas a small number of
characterized MSCs were observed (0.15 to 0.5% of MSC injected cells). This proportion of 
grafted MSCs in the lungs is in adequacy with the current literature, and showed no increase 
in cell engraftment despite lung inflammation, a result that has already been observed in other 
animal models [37]. On the other hand, the mechanisms by which such small MSC number 
suppresses airway responsiveness remain largely unexplained [38]. 
Recent observations suggest that under many conditions MSCs only transiently appear in 
injured tissues, but during their brief appearance they cross-talk with injured cells to limit 
tissue destruction or enhance repair by a variety of mechanisms [10, 38, 39]. Activated MSCs 
secrete COX-2, and as a result, MSCs increase PGE2 secretion that drives resident 
macrophages with an M1 proinflammatory phenotype toward an M2 anti-inflammatory 
phenotype [22]. M2 macrophages show high phagocytic activity, they produce low amounts 
of pro-inflammatory cytokines and higher amounts of the anti-inflammatory cytokine IL-10, 
and they contribute to inflammation resolution [21]. In our study, MSC injection induced lung 
macrophage polarization into M2 suppressive phenotype, without inducing an increase in 
macrophage number, as already observed in ovalbumin-induced allergic model [40]. In turn, 
injected MSCs expressed 10 to 100 fold more COX-2 than before injection, suggesting that 
MSC phenotype alteration occurred after in vivo injection, in presence or absence of 
inflammation. Interestingly, MSCs need to be viable when injected, as delivery of PFA-fixed 
MSCs to allergen-sensitized mice resulted in severe pathology [13]. Importantly, the 
induction of M2 suppressive phenotype was observed in our study only in macrophages that 
had phagocyted PKH26
+
 MSCs and not in “naive” macrophages (i.e., PKH26
-
 macrophages),
suggesting that M2 suppressive phenotype was induced by MSC phagocytosis and not by 
simple cross-talk between macrophages and MSCs. In summary these data demonstrate that 
Page 15 of 37 Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16
injected MSCs in vivo are phagocyted in the lungs after i.v. injection, inducing a suppressive 
macrophage cellular phenotype. By doing this, MSCs promote the establishment of a 
tolerogenic microenvironment that might probably counterbalance T-cell mediated airway 
inflammation. 
It is strongly believed that MSCs achieve a therapeutic effect in vivo via paracrine action, in 
particular the shedding of extracellular vesicles including exosomes and microvesicles [41]. 
Under standard in vitro culture conditions, Phinney et al recently demonstrated that MSCs 
undergo mitophagy and use microvesicles to unload mitochondria, which are engulfed by 
macrophages and re-utilized to increase bioenergetics [42]. In our study, to label MSCs prior 
to in vivo injection we used PKH26 labelling, a fluorescent red marker which stably 
incorporates into cell membrane lipids. Therefore, PKH26+ macrophages in lung suspensions 
may be macrophages that have phagocyted exosomes with PKH26+ membranes, without 
phagocyting whole MSCs. However, this mechanism cannot explain the low number of 
surviving MSCs 24hr after in vivo administration (less than 0.5%), suggesting that MSC 
phagocytosis by macrophages is, at least in part, responsible for low MSC surviving. 
We chose a house dust mite mice allergic asthma model, because house dust mite is the main 
indoor allergens responsible for human asthma, and this model being characterized by 
abnormal TH2 and TH17 immune response as observed in patients with severe asthma [19]. 
MSC injection at day 0 before Der f sensitization did not prevent the alteration in respiratory 
function during subsequent Der f challenges in our model (data not shown). This suggests that 
MSC injection did not protect from sensitization to new allergen but could attenuate 
deleterious reaction to repeated allergen exposure and prevent further asthma exacerbation 
and remodeling. Similar to our results, MSC injection could modulate airway inflammation in 
chronic asthma model when MSCs were administered during the installation of inflammation 
[23]. 
Page 16 of 37
ScholarOne Support: (434) 964-4100
Stem Cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17
MSC administration decreased significantly airway hyper-responsiveness induced by 
methacholine only in asthmatic Der f mice, and this result correlated with the reduction of ex 
vivo primary bronchial contraction. Furthermore MSC injection increased M2 muscarinic 
receptor expression in asthmatic mice. Low or dysfunctional M2 muscarinic receptor activity 
has been associated with airway hyper-responsiveness in mice [43]. M2 muscarinic receptor 
inhibited the release of acetylcholine, a cholinergic neurotransmitter typically increased in 
asthmatic patients, promoting airway contraction [44]. MSC injection induced a diminution of 
eosinophils and IL-5, two factors influencing the M2 muscarinic receptor expression [45, 46]. 
In summary, our data suggest that the mechanism of airway hyper-responsiveness decrease by 
MSC injection was not limited to a modification of inflammation response as observed in 
numerous studies [47], but was also linked to a modification of airway contractility. 
Conclusion: 
Cell engraftment after i.v injection to repair injured tissue has always been a challenge since 
the beginning of cell therapy studies. We showed in a mouse model of asthma that most of 
injected MSCs, not only do not engraft into lungs but are in vivo phagocyted by lung 
macrophages which, in turn, acquire a M2 suppressive phenotype. This mechanism was 
sufficient to decrease airway responsiveness and to observe MSC anti-inflammatory efficacy. 
As MSCs are being used for their immunomodulatory properties in the treatment of a number 
of immune-based disorders [48], further studies on such mechanisms in other models and to 
unravel early in vivo interactions between MSCs and lung macrophages are warranted. 
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Figure legends 
Figure 1 : Allergic asthma protocol. 
Mice were sensitized by percutaneous administrations of total house dust mite (Der f) extracts 
or DMSO for controls, once a week during 4 weeks, and challenged by intranasal instillations 
of Der f extracts or PBS for controls, once a week during 2 weeks. 5.10
5
 MSCs in 200µL PBS
or 200 µL PBS in control mice were injected in tail vein during the first challenge at day 27. 
Analyses were performed at day 28 (24hr after MSC injection), at day 35 (1 day after the last 
challenge) or at day 37 (3 days after the last challenge). 
Figure 2: Mesenchymal stem cells inhibit airway hyper-responsiveness and 
bronchoconstriction. 
(A) Airway resistance was measured using Flexivent
®
 after instillation of 0 to 20mg/mL
methacholine, in control and asthmatic Der f mice that had received PBS (as a control) or 
5.10
5
 MSCs, respectively, at day 27 following first Der f sensitization. Measurements were
realized at day 35 in control mice, and at day 35 and 37 following first Der f sensitization (1 
or 3 days after the second challenge, respectively) in Der f mice. Data are means ± SEM. (B) 
Contractile response of primary bronchi (2 mm-long rings) from control and Der f asthmatic 
mice injected with PBS or MSCs, stimulated with KCl or carbachol. Measurements were 
performed in 2 primary bronchi per each mouse at day 37. Data are means ± SEM. (C) 
Relative mRNA expression levels of M2 and M3 muscarinic receptors, evaluated by real-time 
PCR in primary bronchi from control and Der f asthmatic mice injected with PBS or MSCs. 
mRNA transcription level was normalized to HPRT1 expression. Data are expressed as means 
± SD. ** p<0.01 compared to control + PBS mice. Statistical differences were determined by 
a Mann Whitney test, ** p<0.01; * p<0.05. 
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Figure 3: Mesenchymal stem cells were located in alveolar walls and capillary walls after 
i.v. injection. 
Each panel shows representative images of histological fluorescence analysis (A,C,E,G), 
followed by H&E staining (B,D,F,H) of the same lung sections, from control and asthmatic 
Der f mice sacrificed 24hr (Day 28) and 10 days (Day 37) after PKH26
+
 MSC injection.
Smaller panels are zoomed images of the dotted rectangles. DAPI (blue) stained nuclei and 
anti-CD45 antibody (green) stained leucocytes. PKH26
+
 cells (arrow and red) were located in
alveolar walls and capillary walls in both control and asthmatic mice, and in inflammatory 
infiltrates in asthmatic mice. *: alveolus. **: airway bronchiole. Scale bar: 50 µm.
Figure 4: Characterization of the PKH26
+
 injected MSCs. 
Lungs were removed and digested with collagenase in control or Der f mice, 24hr (Day 28) or 
10 days (Day 37) after i.v. injection of PKH26
+
 labelled MSCs, to obtain lung single-cell
suspensions. Lung cells were then labelled with DAPI, CD11c and F4/80 antibodies. (A) 
Representative example of flow cytometric analysis and sorting at day 28 in lung cell 
suspension from a control mouse injected with PKH26
+
 labelled MSCs. PKH26
+
 cells were
identified in lung cell suspension (PKH26 vs FSC-H, upper panel). After gating on this 
PKH26
+
 cells, PKH26
+
 cells were sorted according to the presence or absence of expression
of both CD11c and F4/80 macrophage markers (CD11c vs F4/80, low panel). (B) 
Representative images of cell plates containing PKH26
+
CD11c
+
F4/80
+ 
and PKH26
+
CD11c
-
F4/80
- 
sorted cells and cultured separately in MSC culture medium. 
PKH26
+
CD11c
+
F4/80
+
sorted cells (upper panels) did not proliferate and had round shape
morphology, whereas PKH26
+
CD11c
-
F4/80
- 
sorted cells (lower panels) proliferated, requiring
2 to 4 cell passages, and presented with long shape morphology. (C-D) Absolute numbers of 
PKH26
+
CD11c
+
F4/80
+ 
sorted cells (C) and PKH26
+
CD11c
-
F4/80
- 
sorted cells (D), 24hr and
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10 days after PKH26
+ 
MSC injection. Statistical differences were determined by a Mann
Whitney test,**p<0.01; * p<0.05, ns : not significant. 
Figure 5: Injection of mesenchymal stem cells decreased airway inflammation 
(A) Total number of macrophages (Mac), neutrophils (PMN), eosinophils (PNE) and 
lymphocytes (Lym), were obtained by flow cytometry on bronchoalveolar lavages at day 28 
in control and Der f mice injected with PBS or with MSCs. Data are expressed as means ± 
SD. 
(B) Percentage of IL-4, IL-5, IL-13, IL-17, IFNγ, and IL-10 positive CD4
+
 T cells isolated
from the lungs at day 28, from control and Der f mice injected with PBS or with MSCs. Data 
are expressed as means ± SD. Statistical differences were determined by a Mann Whitney 
test, ** p<0.01; * p<0.05, ns : not significant. 
Figure 6: MSC injection induced macrophage polarization into suppressive phenotype 
in the lungs 
A) Relative mRNA expression levels of TGFβ1, IL-10, IL-6 and TNFα in PKH26
+
(PKH26
+
CD11c
+
F4/80
+
)
 
and PKH26
-
 (PKH26
-
CD11c
+
F4/80
+
)
 
macrophages sorted from lung
cell suspensions using flow cytometry. Measurements were performed at day 28 (24hr after 
PKH26
+
 MSC injection) in control (n=6 to 8) and Der f mice (n=5 to 6). (B) Relative COX-2
mRNA expression levels in MSCs in vitro just before injection (n=5), and in PKH26
+
CD11c
-
F4/80
-
 cells (PKH26
+
 MSCs) cells sorted from lung cell suspensions using flow cytometry.
Measurements were performed in control mice (n=2 to 7) and in Der f mice (n=3 to 6) at day 
28 (24hr after PKH26
+
 MSC injection) and day 37 (10 days after PKH26
+
 MSC injection).
mRNA expression was expressed in logarithmic scale. mRNA transcription level was 
normalized with HPRT1 expression. Statistical differences were determined by a Mann 
Whitney test, ** p<0.01 and * p<0.05. 
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Graphical Abstract 
Lung macrophages have been cell-sorted from lung cell suspensions, 24hr after intravenous 
injection of PKH26+ mesenchymal stem cells (MSCs). PKH26 staining is characterized by 
incorporation of red fluorescent molecules into the cell membrane and induces intense and 
reproducible fluorescence. Lung macrophages show PKH26+ (red) labelling, suggesting that 
they had in vivo phagocyted the PKH26+ MSCs. 
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Supplementary Figure 1 : Mesenchymal stem cell characterization. 
After passage 8, MSCs isolated from BALB/c bone marrow were characterized by flow cytometry, and 
by their ability to adipogenic and osteogenic differentiation. (A) Specific MSC phenotype was 
distinguished by Sca-1, CD29, CD44 positive expression, and CD45, CD11b negative expression. (B) 
MSC adipogenic differentiation was characterized by fat drops revealed by Oil Red O labeling. MSC 
osteogenic differentiation was characterized by calcium precipitate revealed by Alizarin Red S 
 labelling. Controls are MSCs 
cultured in MSC medium. 
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Supplementary Figure 2 : Strategy of gating for cells sorting by flow cytometry. 
Representative images for cell isolation by flow cytometry at day 28 in Der f + MSC and Der f + 
PBS mice. Cells were sorted after gating for morphology (FSC-H vs FSC-A) and viability 
(negative for DAPI). On these gates, cells PKH26+ and PKH26- were identified and further 
selected for cells sorting by F4/80 and CD11c expression. 
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Supplementary Figure 3 : Sorted cell characterization after in vitro culture 
(A) After 19 days of culture PKH26+CD11c+F4/80+ cells sorted by flow cytometry expressed 
macrophage specific markers (F4/80, CD11c) confirming that these cells were macrophages. 
(B) After 31 days of culture and 3 passages, PKH26+ CD11c- F4/80- cells sorted by flow cytometry 
showed MSC specific phenotype (Sca-1+, CD44+, CD29+, CD45-, CD11b-) confirming that these cells 
were the injected PKH26+ MSCs. 
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